These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18281557)
1. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138 [TBL] [Abstract][Full Text] [Related]
3. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357 [TBL] [Abstract][Full Text] [Related]
4. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Lun XQ; Zhou H; Alain T; Sun B; Wang L; Barrett JW; Stanford MM; McFadden G; Bell J; Senger DL; Forsyth PA Cancer Res; 2007 Sep; 67(18):8818-27. PubMed ID: 17875723 [TBL] [Abstract][Full Text] [Related]
5. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Lun X; Yang W; Alain T; Shi ZQ; Muzik H; Barrett JW; McFadden G; Bell J; Hamilton MG; Senger DL; Forsyth PA Cancer Res; 2005 Nov; 65(21):9982-9990. PubMed ID: 16267023 [TBL] [Abstract][Full Text] [Related]
6. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772 [TBL] [Abstract][Full Text] [Related]
8. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus. Zhang P; Han X; Tan W; Chen D; Sun Q Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer. Zhao X; Huang S; Luo H; Wan X; Gui Y; Li J; Wu D Int J Clin Exp Med; 2014; 7(5):1204-13. PubMed ID: 24995075 [TBL] [Abstract][Full Text] [Related]
11. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors. Gao Y; Bergman I J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666 [TBL] [Abstract][Full Text] [Related]